CRN01941

CRN01941 is an optimized, selective, orally available small molecule that acts as a nonpeptide biased agonist of the somatostatin receptor subtype 2 (sst2). It was developed by Crinetics Pharmaceuticals for the treatment of neuroendocrine tumors (NETs) originating from neuroendocrine cells in the gut, lung, or pancreas. The drug is highly selective for sst2 over other somatostatin receptor subtypes and demonstrates strong bias for Gi signaling versus receptor internalization. In preclinical models, it potently inhibited growth hormone-releasing hormone (GHRH)-induced growth hormone production. Despite entering Phase 1 clinical trials to evaluate safety and pharmacokinetics in healthy volunteers, development was discontinued after early results did not show improvement over paltusotine[1][3][6].